Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00005098 · ClinicalTrials.gov registry record

Study of Genotype and Phenotype in Patients With Alpha 1-Antitrypsin Deficiency

A clinical trial, sponsored by National Center for Research Resources (NCRR).

Terminated
Registry status
160
Enrollment target

NCT00005098: Clinical Trial study, sponsored by National Center for Research Resources (NCRR).

NCT00005098 is a clinical trial that was terminated before completion, run by National Center for Research Resources (NCRR). The registered enrollment target is 160 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00005098 was terminated before completion, sponsored by National Center for Research Resources (NCRR).

TERMINATED
Registry status
160 participants
Enrollment target

Study Summary

OBJECTIVES: I. Establish cell lines from patients with alpha 1-antitrypsin deficiency in order to examine genetic traits that predispose to liver injury.

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 1999-03

Why NCT00005098 stopped before completion

NCT00005098 is an observational study that tracks outcomes without assigning an intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT00005098 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00005098 about?

NCT00005098 is a clinical study titled "Study of Genotype and Phenotype in Patients With Alpha 1-Antitrypsin Deficiency". OBJECTIVES: I. Establish cell lines from patients with alpha 1-antitrypsin deficiency in order to examine genetic traits that predispose to liver injury.

What is the current status of trial NCT00005098?

This trial is currently terminated. The enrollment target is 160 participants. The study started on 1999-03.

Who is sponsoring clinical trial NCT00005098?

This trial is sponsored by National Center for Research Resources (NCRR), which has 94 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00501826 · 160 participants · Phase 2

    Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

  • NCT00932139 · 160 participants · NA

    Effect of Electro-Acupuncture on Blood Pressure

  • NCT00992901 · 160 participants · Early Phase 1

    Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery

  • NCT01515527 · 160 participants · Phase 2

    Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00005098, the US trial registry maintained by the National Library of Medicine. NCT00005098 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.